Author

Samhita Iyer

Institution: Tyra Biosciences (United States)

Observed institutions: University of California San Diego, Moores Cancer Center, Tyra Biosciences (United States)

ORCID: 0000-0002-9514-5477

Observed ORCID: 0000-0002-9514-5477

OpenAlex ID: A5012440591

Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis

2022 · Duygu Ozmadenci, Jayanth S. Shankara Narayanan, et al. · Proceedings of the National Academy of Sciences · 83

Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia

2024 · Robert L. Hudkins, Eric Allen, et al. · Journal of Medicinal Chemistry · 37

Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity

2025 · Jacqueline H. Starrett, Eric L. Allen, et al. · Molecular Cancer Therapeutics · 3

Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance Mutations

2026 · Robert L. Hudkins, Eric Allen, et al. · Journal of Medicinal Chemistry · 1

Supplementary Data from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity

2026 · Jacqueline H. Starrett, Eric L. Allen, et al.

Figure 2 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity

2026 · Jacqueline H. Starrett, Eric L. Allen, et al.

Figure 1 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity

2026 · Jacqueline H. Starrett, Eric L. Allen, et al.

Figure 3 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity

2026 · Jacqueline H. Starrett, Eric L. Allen, et al.

Data from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity

2026 · Jacqueline H. Starrett, Eric L. Allen, et al.

Figure 4 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity

2026 · Jacqueline H. Starrett, Eric L. Allen, et al.

Works count: 10

Citation count: 124

H-index: 3

I10-index: 2